Yes, very interesting. An idle thought occurred especially after reading the comment by Josh Munter;
as well as smaller, more nimble trials that should require less burn as well as quicker time to readouts.
For my purposes, assume two or three of the current batch of product receive a BLA over time, yes of course 3 is better than 2. Sometimes I like to sort of conservative.
We have already heard of various drivers for off label extensions for Ryoncil, now imagine that for either Revascor or MPC-06-ID. I can imagine all sorts of off label uses for MPC-06-ID to do with some kinds of joint pains. Revascor and leaky intestines, inflammation in general, where could that go? No idea personally but others have been pointing the way for a while now.
Already registered, just off label, opens the way the lots of smaller more nimble trials for the most part funded by other parties, I'm also guessing that this is where the MOU that was signed by INCHOIR and Mesoblast might be a forerunner.
Along the way there will be $ for bringing on the next generation products.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)